Document Detail

Mycophenolate mofetil treatment in children and adolescents with lupus.
MedLine Citation:
PMID:  20810399     Owner:  NLM     Status:  MEDLINE    
Safety and efficacy data are presented on the use of mycophenolate mofetil (MMF) in 26 children and adolescents with lupus. Data include therapy before and 12 months after starting MMF. 18 of 26 patients had biopsy-proved lupus nephritis. Group 1 were commenced on MMF induction and/or maintenance therapy (n=14), group 2 converted from azathioprine because of inadequate disease control (n=12). 73% of all (10 (71%) group 1 and 10 (83%) group 2) patients experienced a significant improvement in British Isles Lupus Assessment Group score (from median 9.0 to 3.0). Children with hypocomplementaemia increased their C3 significantly in both groups (0.53-1.15 for group 1 and 0.63-1.2 g/l for group 2, p=0.001), and C4 level only in group 1 (0.08-0.17, p=0.01). Renal function and albuminuria improved in those with active nephritis (p≤0.01). Significant improvements were seen in both groups in haemoglobin, erythrocyte sedimentation rate and lymphocyte counts. Prednisolone dose was weaned in both groups, p<0.05. Side-effects were seen in four patients, but none was judged to be severe enough to discontinue treatment. MMF treatment in this cohort of children with lupus seemed to be safe, well tolerated and effective.
Ina Kazyra; Clarissa Pilkington; Stephen D Marks; Kjell Tullus
Related Documents :
20659409 - Burden of autoantibodies and association with disease activity and damage in systemic l...
9413429 - Cytotoxic therapy in systemic lupus erythematosus. experience from a single center.
8039279 - Ultraviolet-a1 irradiation decreases clinical disease activity and autoantibodies in pa...
19845819 - Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis.
14999109 - Sequential therapies for proliferative lupus nephritis.
18159379 - Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in...
18071079 - Effects of angiotensin-converting enzyme inhibition in low-risk patients early after co...
24694519 - In-line hemofiltration minimized extracorporeal membrane oxygenation-related inflammati...
23013849 - Wait times for rheumatology consultation: is rheumatoid arthritis prioritized?
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2010-08-31
Journal Detail:
Title:  Archives of disease in childhood     Volume:  95     ISSN:  1468-2044     ISO Abbreviation:  Arch. Dis. Child.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-26     Completed Date:  2010-12-28     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  0372434     Medline TA:  Arch Dis Child     Country:  England    
Other Details:
Languages:  eng     Pagination:  1059-61     Citation Subset:  AIM; IM    
Department of Paediatrics, Belarus State Medical University, Minsk, Belarus.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Child, Preschool
Complement C3 / metabolism
Complement C4 / metabolism
Drug Administration Schedule
Drug Therapy, Combination
Glucocorticoids / administration & dosage
Immunosuppressive Agents / adverse effects,  therapeutic use*
Lupus Erythematosus, Systemic / drug therapy*,  immunology
Lupus Nephritis / drug therapy
Mycophenolic Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Prednisolone / administration & dosage
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Reg. No./Substance:
0/Complement C3; 0/Complement C4; 0/Glucocorticoids; 0/Immunosuppressive Agents; 24280-93-1/Mycophenolic Acid; 50-24-8/Prednisolone; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Compliance with NICE guidelines for urinary tract infections: a survey among the paediatric trainees...
Next Document:  Children's access to treatment for epilepsy: experience from the Lao People's Democratic Republic.